Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Eli lilly and company crawled time : 16:20 save search
Lilly's Retevmo® (selpercatinib) Phase 3 Results in RET Fusion-Positive Non-Small Cell Lung Cancer and RET-Mutant Medullary Thyroid Cancer Both Published in The New England Journal of Medicine and Presented in a Presidential Symposium at ESMO Congress 2023
Published: 2023-10-21 (Crawled : 16:20) - prnewswire.com
LLY | News | $741.37 1.37% 800K
|
Health Technology
| Email alert
Add to watchlist
retevmo lung congress symposium cancer cell thyroid results
Lilly's SURMOUNT-2 results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes
Published: 2023-06-24 (Crawled : 16:20) - prnewswire.com
LLY | News | $741.37 1.37% 800K
|
Health Technology
| Email alert
Add to watchlist
obesity lancet diabetes results show tirzepatide
Merus Provides 2023 Outlook
Published: 2023-01-08 (Crawled : 16:20) - globenewswire.com
MRUS | $41.37 2.27% 250K
|
Health Technology
| Email alert
Add to watchlist
LLY | News | $741.37 1.37% 800K
|
Health Technology
| Email alert
Add to watchlist
How The World’s First Home Gaming System Was Made In Indiana
Published: 2022-09-11 (Crawled : 16:20) - emmis.com
LLY | News | $741.37 1.37% 800K
|
Health Technology
| Email alert
Add to watchlist
system home
Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight
Published: 2022-06-04 (Crawled : 16:20) - prnewswire.com
LLY | News | $741.37 1.37% 800K
|
Health Technology
| Email alert
Add to watchlist
obesity results tirzepatide
Lilly's AWARD-PEDS trial investigating use of Trulicity® (dulaglutide) in youth and adolescents with type 2 diabetes showed superiority in A1C reduction vs placebo
Published: 2022-06-04 (Crawled : 16:20) - prnewswire.com
LLY | News | $741.37 1.37% 800K
|
Health Technology
| Email alert
Add to watchlist
trulicity trial diabetes
Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly's Pivotal Phase 3 Atopic Dermatitis Studies
Published: 2022-03-26 (Crawled : 16:20) - prnewswire.com
LLY | News | $741.37 1.37% 800K
|
Health Technology
| Email alert
Add to watchlist
clearance dermatitis skin phase 3
Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies
Published: 2022-03-26 (Crawled : 16:20) - prnewswire.com
LLY | News | $741.37 1.37% 800K
|
Health Technology
| Email alert
Add to watchlist
INCY | $52.02 0.19% 1.2M
|
Health Technology
| Email alert
Add to watchlist
olumiant phase 3
Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates
Published: 2022-02-24 (Crawled : 16:20) - ir.cyclerion.com
LLY | News | $741.37 1.37% 800K
|
Health Technology
|
| O: 3.94%
H: 0.0%
C: 0.0%
CYCN | $3.05 110
|
Health Technology
|
| O: 0.4%
H: 3.0%
C: -3.87%
cy6463 ces
Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for Pirtobrutinib at the American Society of Hematology Annual Meeting
Published: 2021-12-12 (Crawled : 16:20) - prnewswire.com
LLY | News | $741.37 1.37% 800K
|
Health Technology
| Email alert
Add to watchlist
ema trial phase 1
Junshi Biosciences Announces Expansion of Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Post-Exposure Prophylaxis for COVID-19
Published: 2021-09-19 (Crawled : 16:20) - globenewswire.com
LLY | News | $741.37 1.37% 800K
|
Health Technology
| Email alert
Add to watchlist
covid expansion merge authorized emergency use authorization
Gainers vs Losers
| 87% | 13% |
Top 10 Gainers
MTTR | News M | $4.64 166.67% 18M
|
AGBA | $2.74 119.2% 52M
|
Finance
CZOO | $9.07 81.76% 22M
|
EDBL | News | $6.56 74.47% 1.8M
|
OPRT | News | $3.37 49.78% 8.9M
|
Finance
MTC | $2.14 37.18% 4.9M
|
Technology Services
VNRX | $0.7945 32.42% 3.1M
|
Health Technology
MLEC | $1.79 27.86% 2.6M
|
n/a
BTCM | $3.45 27.78% 640K
|
Arts, Entertainment, and Recrea...
PALI | $6.29 27.59% 22M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.